article thumbnail

Anthos Presents New Analysis from P2 AZALEA-TIMI 71 Study

DAIC

Patient Demographics: Patients on APT had a higher rate of coronary artery disease (70% vs. 42%), previous heart attacks (36% vs. 16%), and peripheral artery disease (15% vs. 11%). For more information, please visit anthostherapeutics.com.

article thumbnail

Chronic exposure to lead, cadmium and arsenic increases risk of cardiovascular disease

Science Daily - Stroke

Around the world, most people are regularly exposed to low or moderate levels of lead, cadmium and arsenic in the environment, increasing risk of coronary artery disease, stroke and peripheral artery disease, according to a new statement.

article thumbnail

Prevalence of Peripheral Arterial Disease in Patients With Coronary Artery Disease After Cardiac Catheterization: A Prospective Observational Study

The American Journal of Cardiology

Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): Sanjot S. Sunner, Robert C. Welsh, Kevin R.

article thumbnail

Scientists find cancer-like features in atherosclerosis, spurring opportunity for new treatment approaches

Science Daily - Heart Disease

Researchers have discovered that the smooth muscle cells that line the arteries of people with atherosclerosis can change into new cell types and develop traits similar to cancer that worsen the disease.

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.

article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). Jörg Pochert, President of Vascular Intervention at Biotronik.

article thumbnail

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan area of Brandenburg, Germany

Frontiers in Cardiovascular Medicine

Results Brandenburg patients with cardiovascular diseases showed higher Lp(a) levels than healthy controls (24.2% vs. 14.8%, p  = 0.001), and the high-Lp(a) group demonstrated a higher prevalence of coronary artery disease, peripheral artery disease, or cerebrovascular disease than the low-Lp(a) group ( p  = 0.004).